Breast cancer
CDK4/6 inhibitors for everyone? First-line treatment strategies in HR+ HER2- MBCEleonor (62 years old)
Eleonor, 62 years old, is a lawyer, who lives with her husband and 2 daughters in Paris. She was diagnosed 1 year ago with a stage III ER+ HER2- breast cancer, and she is now receiving adjuvant treatment with abemaciclib and letrozole (started 10 months ago). Due to a persistent cough, she underwent a CT scan of the thorax that revealed a suspicious lesion of the right lung.
Assessment summary:
- Postmenopausal
- Medical history: smoking (40 pack years)
- Imaging:
- 2 cm peribronchial pulmonary lesion of the right lung
- 4 suspicious lesions in bones (right scapula, sternum, spine)
- Biopsy of lung lesion: breast cancer, NST, ER 60%, PgR 10%, HER2 IHC 0, G2
- Haematology: all values normal
- Germline BRCA-status: wild type
- Somatic testing: PIK3CA wild type, ESR1 wild type